1
|
Radonic S, Schneider U, Besserer J, Meier VS, Rohrer Bley C. Risk adaptive planning with biology-based constraints may lead to higher tumor control probability in tumors of the canine brain: A planning study. Phys Med 2024; 119:103317. [PMID: 38430675 DOI: 10.1016/j.ejmp.2024.103317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 11/27/2023] [Accepted: 02/06/2024] [Indexed: 03/05/2024] Open
Abstract
BACKGROUND Classical radiation protocols are guided by physical dose delivered homogeneously over the target. Protocols are chosen to keep normal tissue complication probability (NTCP) at an acceptable level. Organs at risk (OAR) adjacent to the target volume could lead to underdosage of the tumor and a decrease of tumor control probability (TCP). The intent of our study was to explore a biology-based dose escalation: by keeping NTCP for OAR constant, radiation dose was to be maximized, allowing to result in heterogeneous dose distributions. METHODS We used computed tomography datasets of 25 dogs with brain tumors, previously treated with 10x4 Gy (40 Gy to PTV D50). We generated 3 plans for each patient: A) original treatment plan with homogeneous dose distribution, B) heterogeneous dose distribution with strict adherence to the same NTCPs as in A), and C) heterogeneous dose distribution with adherence to NTCP <5%. For plan comparison, TCPs and TCP equivalent doses (homogenous target dose which results in the same TCP) were calculated. To enable the use of the generalized equivalent uniform dose (gEUD) metric of the tumor target in plan optimization, the calculated TCP values were used to obtain the volume effect parameter a. RESULTS As intended, NTCPs for all OARs did not differ from plan A) to B). In plan C), however, NTCPs were significantly higher for brain (mean 2.5% (SD±1.9, 95%CI: 1.7,3.3), p<0.001), optic chiasm (mean 2.0% (SD±2.2, 95%CI: 1.0,2.8), p=0.010) compared to plan A), but no significant increase was found for the brainstem. For 24 of 25 of the evaluated patients, the heterogenous plans B) and C) led to an increase in target dose and projected increase in TCP compared to the homogenous plan A). Furthermore, the distribution of the projected individual TCP values as a function of the dose was found to be in good agreement with the population TCP model. CONCLUSION Our study is a first step towards risk-adaptive radiation dose optimization. This strategy utilizes a biologic objective function based on TCP and NTCP instead of an objective function based on physical dose constraints.
Collapse
Affiliation(s)
- Stephan Radonic
- Department of Physics, University of Zurich, Zurich, Switzerland; Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
| | - Uwe Schneider
- Department of Physics, University of Zurich, Zurich, Switzerland; Radiotherapie Hirslanden AG, Rain 34, Aarau, Switzerland
| | - Jürgen Besserer
- Department of Physics, University of Zurich, Zurich, Switzerland; Radiotherapie Hirslanden AG, Rain 34, Aarau, Switzerland
| | - Valeria S Meier
- Department of Physics, University of Zurich, Zurich, Switzerland; Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Carla Rohrer Bley
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Arz R, Seehusen F, Meier VS, Nolff MC. Indocyanine-based near-infrared lymphography for real-time detection of lymphatics in a cat with multiple mast cell tumours. JFMS Open Rep 2022; 8:20551169221074961. [PMID: 35251677 PMCID: PMC8891856 DOI: 10.1177/20551169221074961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Case summary An 11-year-old female domestic shorthair cat was presented with cutaneous mast cell tumours (MCTs) localised at the right temporal region, the left buccal region and on the third digit of the right thoracic limb. Staging was negative and locoregional lymph nodes appeared normal, based on clinical findings. During surgery, real-time indocyanine green (ICG)-based lymphography was performed to detect the cutaneous draining pattern of all the primary MCTs. ICG was injected intracutaneously in four quadrants around each tumour, and a clear lymphogram was visible shortly after injection. Using near-infrared lymphography (NIR-L) for guidance, all lymphadenectomies were performed in 12 mins or less, with a maximal incision length of 3.5 cm. The smallest resected node was 0.9 cm in diameter. All MCTs were classified as low-grade cutaneous MCT. All four ICG-positive lymph nodes were considered premetastatic or metastatic. The only ICG-negative resected node was also negative for tumour cells. No complications related to NIR-L were recorded. Relevance and novel information This is the first description of NIR-L in a cat with MCT. Application was straightforward and ICG enrichment only occurred in the metastatic nodes, suggesting correct identification of lymphatic draining patterns. Of note, as previously described in dogs, we did detect nodal metastasis, despite low-grade primary tumours. The clinical relevance should be evaluated in future studies.
Collapse
Affiliation(s)
- Raphael Arz
- Clinic for Small Animal Surgery, Department for Small Animals, Vetsuisse Faculty, University of Zurich, Switzerland
| | - Frauke Seehusen
- Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Switzerland
| | - Valeria S Meier
- Clinic for Oncology and Radiation Oncology, Department for Small Animals, Vetsuisse Faculty, University of Zurich, Switzerland
- Department of Physics, University of Zurich, Switzerland
| | - Mirja C Nolff
- Clinic for Small Animal Surgery, Department for Small Animals, Vetsuisse Faculty, University of Zurich, Switzerland
| |
Collapse
|
3
|
Toyloy M, Tresch N, Raetz K, Dennler M, Körner M, Meier VS, Rohrer Bley C. [Massive unresectable hepatocellular carcinoma in a dog treated with -intensity-modulated radiation therapy]. SCHWEIZ ARCH TIERH 2021; 163:505-513. [PMID: 34193402 DOI: 10.17236/sat00311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
INTRODUCTION This case report describes a 12-year-old female spayed mixed-breed dog referred for treatment of a large, inoperable hepatocellular carcinoma. A computed tomography (CT) scan confirmed the previous ultrasonographic and laparoscopic findings of a large, lobulated, poorly defined mass on the left and central aspect of the liver. Multiple biopsies confirmed the diagnosis of hepatocellular carcinoma. Due to the large extent of the tumor, the vascular association to the Vena cava caudalis and the associated high risk of intraoperative bleeding, a resection of the mass was refrained from and a radiotherapeutic treatment was chosen. The dog underwent radiation therapy (RT) with a 6MV linear accelerator with 5×6 Gy, total dose 30 Gy. In the follow up examinations three months and one year after therapy, the dog presented in normal condition and had normal Alanine-amino-transferase (ALT) and alkaline phosphatase (AP). The tumor size measured in the CT-examinations decreased by 61% and 90%, respectively. Two years after radiation therapy the dog has a normal general condition and liver enzymes are within the normal limits.
Collapse
Affiliation(s)
- M Toyloy
- Abteilung Radio-Onkologie, Departement für Kleintiere, Vetsuisse-Fakultät, Universität Zürich
| | - N Tresch
- Abteilung Radio-Onkologie, Departement für Kleintiere, Vetsuisse-Fakultät, Universität Zürich
| | - K Raetz
- Bessy's Kleintierklinik, Watt/Regensdorf, Schweiz
| | - M Dennler
- Klinik für bildgebende Diagnostik, Vetsuisse-Fakultät, Universität Zürich
| | - M Körner
- Abteilung Radio-Onkologie, Departement für Kleintiere, Vetsuisse-Fakultät, Universität Zürich
| | - V S Meier
- Abteilung Radio-Onkologie, Departement für Kleintiere, Vetsuisse-Fakultät, Universität Zürich.,Physik-Institut, Universität Zürich, Schweiz
| | - C Rohrer Bley
- Abteilung Radio-Onkologie, Departement für Kleintiere, Vetsuisse-Fakultät, Universität Zürich
| |
Collapse
|
4
|
Bass D, Schuppisser C, Meier VS. Kleintiermedizin: Was ist Ihre Diagnose? SCHWEIZ ARCH TIERH 2021; 163:301-308. [PMID: 33821803 DOI: 10.17236/sat00300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- D Bass
- VET Zentrum AG, Überweisungsklinik für Hunde und Katzen, Pfungen, Schweiz
| | - C Schuppisser
- VET Zentrum AG, Überweisungsklinik für Hunde und Katzen, Pfungen, Schweiz
| | - V S Meier
- Departement für Kleintiere, Abteilung Radio-Onkologie, Vetsuisse-Fakultät, Universität Zürich
| |
Collapse
|
5
|
Wolf F, Meier VS, Pot SA, Rohrer Bley C. Ocular and periocular radiation toxicity in dogs treated for sinonasal tumors: A critical review. Vet Ophthalmol 2020; 23:596-610. [PMID: 32281234 PMCID: PMC7496316 DOI: 10.1111/vop.12761] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Revised: 02/26/2020] [Accepted: 03/16/2020] [Indexed: 12/25/2022]
Abstract
Visual impairment from radiation‐induced damage can be painful, disabling, and reduces the patient's quality of life. Ocular tissue damage can result from the proximity of ocular organs at risk to irradiated sinonasal target volumes. As toxicity depends on the radiation dose delivered to a certain volume, dose‐volume constraints for organs at risk should ideally be known during treatment planning in order to reduce toxicity. Herein, we summarize published ocular toxicity data of dogs irradiated for sinonasal tumors from 36 publications (1976‐2018). In particular, we tried to extract a dose guideline for a clinically acceptable rate of ocular toxicity. The side effects to ocular and periocular tissues were reported in 26/36 studies (72%) and graded according to scoring systems (10/26; 39%). With most scoring systems, however, toxicities of different ocular and periocular tissues are summed into one score. Further, the scores were mostly applied in retrospect and lack volume‐ and dose‐data. This incomplete information reflects the crux of the matter for radiation dose tolerance in canine ocular tissues: The published information of the last three decades does not allow formulating dose‐volume guidelines. As a start, we can only state that a mean dose of 39 Gy (given in 10 x 4.2 Gy fractions) will lead to loss of vision by one or both eyes, while mean doses of <30 Gy seem to preserve functionality. With a future goal to define tolerated doses and volumes of ocular and periocular tissues at risk, we propose the use of combined ocular toxicity scoring systems.
Collapse
Affiliation(s)
- Friederike Wolf
- Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Valeria S Meier
- Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.,Department of Physics, University of Zurich, Zurich, Switzerland
| | - Simon A Pot
- Ophthalmology Section, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Carla Rohrer Bley
- Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| |
Collapse
|
6
|
Stiborova K, Meier VS, Takada M, Turek M, Poirier VJ, Laliberte S, Rohrer Bley C. Definitive-intent radiotherapy for sinonasal carcinoma in cats: A multicenter retrospective assessment. Vet Comp Oncol 2020; 18:626-633. [PMID: 32134553 DOI: 10.1111/vco.12583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Revised: 02/24/2020] [Accepted: 02/26/2020] [Indexed: 11/27/2022]
Abstract
Treatment of epithelial sinonasal tumours in cats is not commonly reported. In the newer reports, palliative radiation protocols have been described more often than definitive-intent protocols. In this multi-institutional retrospective study, we included 27 cats treated with single-modality radiotherapy. Cats were irradiated using 10 daily fractions of 4.2 Gy. Three cats (11.1%) experienced a complete clinical response and 17 (63%) had a partial clinical response. Stable clinical disease was noted in three cats (11.1%). Four cats (14.8%) showed progression within 3 months following treatment. The median time to progression for all cases was 269 days (95 % confidence intervals [CI]: 225; 314). The proportion of cats free of progression at 1 and 2 years was 24% (95% CI: 22%; 26%) and 5% (95% CI: 5%; 6%), respectively. None of the prognostic factors evaluated were predictive of outcome (anaemia, tumour volume at the time of staging, modified Adams stage, intracranial involvement, facial deformity, epistaxis, inappetence or weight loss). Median overall survival (OS) for all deaths was 452 days (95% CI: 334; 571). The proportion of cats alive at 1 and 2 years was 57% (95% CI: 37%; 77%) and 27% (95% CI: 25%; 29%), respectively. Surprisingly, cats with epistaxis had a longer median OS of 828 days (95% CI: 356; 1301) compared to 296 days (95% CI: 85; 508) in cats without epistaxis, (P = .04, Breslow). Radiation therapy used as a single modality for the treatment of feline sinonasal carcinoma improved clinical signs and was well tolerated but progression within a year was common.
Collapse
Affiliation(s)
- Katerina Stiborova
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Valeria S Meier
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.,Department of Physics, University of Zurich, Zurich, Switzerland
| | - Marilia Takada
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Michelle Turek
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Valerie J Poirier
- Animal Cancer Centre, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
| | - Sarah Laliberte
- Animal Cancer Centre, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
| | - Carla Rohrer Bley
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| |
Collapse
|
7
|
Reusch C, Burkhardt WA, Meier VS, Rohrer Bley C, Riond B, Dennler M, Boretti F, Sieber-Ruckstuhl N. [Acromegaly due to a pituitary tumor in a dog - diagnosis, therapy and long-term follow-up]. SCHWEIZ ARCH TIERH 2019; 161:319-327. [PMID: 31064738 DOI: 10.17236/sat00208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
INTRODUCTION Acromegaly due to a pituitary tumor has so far only been described in 3 dogs. The present case report describes a 7-year-old male-castrated Labrador Retriever which was referred because of difficult-to-control diabetes. Physical examination revealed markedly enlarged head, tongue and paws, widened interdental spaces and thickening of the skin in the head and neck area. IGF-1 and GH were increased and the latter continued to be abnormal after somatostatin application. Computed tomography demonstrated a space-occupying lesion in the pituitary gland and the diagnosis of acromegaly due to a GH-producing tumor of the pituitary was made. The dog underwent radiation therapy with a 6MV linear accelerator (3×8Gy) and improved substantially. Two and a half years after radiation therapy the dog developed lethargy and anorexia and was euthanized. Necropsy was not permitted. This case report represents the description of a dog suffering from pituitary-dependent acromegaly which was successfully treated and had a long-term survival.
Collapse
Affiliation(s)
- C Reusch
- Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich
| | - W A Burkhardt
- Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich
| | - V S Meier
- Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich
| | - C Rohrer Bley
- Division of Radiation Oncology, Vetsuisse Faculty, University of Zurich
| | - B Riond
- Clinical Laboratory, Vetsuisse Faculty, University of Zurich
| | - M Dennler
- Clinic of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich
| | - F Boretti
- Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich
| | - N Sieber-Ruckstuhl
- Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich
| |
Collapse
|
8
|
Meier VS, Beatrice L, Turek M, Poirier VJ, Cancedda S, Stiborova K, Körner M, Marconato L, Weyland MS, Rohrer Bley C. Outcome and failure patterns of localized sinonasal lymphoma in cats treated with first-line single-modality radiation therapy: A retrospective study. Vet Comp Oncol 2019; 17:528-536. [PMID: 31254440 DOI: 10.1111/vco.12517] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 06/12/2019] [Accepted: 06/14/2019] [Indexed: 11/28/2022]
Abstract
Failure rate and site are not well defined in localized sinonasal lymphoma in cats treated with radiotherapy. In this study, we describe (a) failure pattern, (b) outcome, (c) influence of previously reported prognostic variables on the outcome in cats with suspected localized sinonasal lymphoma. In this multi-institutional retrospective study, we included 51 cats treated with single-modality radiotherapy. Cats were irradiated using 10x4.2Gy (n = 32), 12x3Gy (n = 11) or 5x6Gy (n = 8). Regional lymph nodes were prophylactically irradiated in 24/51 cats (47.1%). Twenty-five cats (49.0%) developed progressive disease: progression was local (nasal) in five (9.8%), locoregional (nodal) in two (3.9%), local and locoregional in three (5.9%), systemic in nine (17.6%) and both local and systemic in six cats (11.8%). No cat receiving prophylactic nodal irradiation had progression in the locoregional lymph nodes. The median time to progression was 974 days (95%CI: 283;1666), with 58% and 53% of cats free of progression at 1 and 2 years, respectively. Median overall survival was 922 days (95%CI: 66;1779) with 61% and 49% alive at 1 and 2 years, respectively. Half of the cats that died of relapse/progression (13/26) died within 6 months of treatment, suggesting possible shortcomings of staging, rapid dissemination of disease or sequential lymphomagenesis. None of the prognostic factors evaluated were predictive of outcome (prednisolone use, anaemia, nasopharyngeal involvement, modified canine Adams tumour stage, protocol, total dose). Radiotherapy is an effective treatment for localized sinonasal lymphoma with a long time to progression. However, in one-third of the cats, systemic disease progression occurs soon after radiotherapy.
Collapse
Affiliation(s)
- Valeria S Meier
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Laura Beatrice
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Michelle Turek
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Valerie J Poirier
- Animal Cancer Centre, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
| | - Simona Cancedda
- Centro Oncologico Veterinario, Sasso Marconi (Bologna), Italy
| | - Katerina Stiborova
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Maximilian Körner
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Laura Marconato
- Centro Oncologico Veterinario, Sasso Marconi (Bologna), Italy
| | - Mathias S Weyland
- ZHAW School of Engineering, Zurich University of Applied Sciences, Winterthur, Switzerland
| | - Carla Rohrer Bley
- Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| |
Collapse
|
9
|
Rohrer Bley C, Meier VS, Besserer J, Schneider U. Intensity‐modulated radiation therapy dose prescription and reporting: Sum and substance of the International Commission on Radiation Units and Measurements Report 83 for veterinary medicine. Vet Radiol Ultrasound 2019; 60:255-264. [DOI: 10.1111/vru.12722] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Revised: 12/09/2018] [Accepted: 12/31/2018] [Indexed: 12/25/2022] Open
Affiliation(s)
- Carla Rohrer Bley
- Division of Radiation OncologyVetsuisse FacultyUniversity of Zurich Zurich Switzerland
| | - Valeria S. Meier
- Division of Radiation OncologyVetsuisse FacultyUniversity of Zurich Zurich Switzerland
| | - Juergen Besserer
- Division of Radiation OncologyVetsuisse FacultyUniversity of Zurich Zurich Switzerland
- Radiation OncologyHirslanden Clinic Zurich Switzerland
| | - Uwe Schneider
- Division of Radiation OncologyVetsuisse FacultyUniversity of Zurich Zurich Switzerland
- Radiation OncologyHirslanden Clinic Zurich Switzerland
| |
Collapse
|
10
|
Körner M, Roos M, Meier VS, Soukup A, Cancedda S, Parys MM, Turek M, Rohrer Bley C. Radiation therapy for intracranial tumours in cats with neurological signs. J Feline Med Surg 2018; 21:765-771. [PMID: 30339060 DOI: 10.1177/1098612x18801032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES The aim of this study was to evaluate the outcome of cats with intracranial tumours presenting with neurological signs treated with radiation therapy. METHODS This study comprised a retrospective multicentre case series. Medical records of a total of 22 cats with intracranial space-occupying lesions, presenting with neurological signs and/or epileptic seizures and treated with external beam radiation therapy, were reviewed. In the treated cats, patient-, tumour- and treatment-related variables were investigated, including age, sex, tumour location, tumour volume, total radiation dose, equivalent dose in 2 Gy fractions (EQD2), corticosteroid dose, overall treatment time and institution for influence on local tumour control and survival. RESULTS Based on advanced imaging characteristics, the 22 treated cats presented with meningioma (n = 11), pituitary tumour (n = 8), choroid plexus tumour (n = 2) or glioma (n = 1). Allocated to the neuraxis, 11 lesions were extra-axial, three were intra-axial and eight were located in the pituitary region. At diagnosis, 21 cats exhibited altered neurological status. One cat presented with epileptic seizures and another cat had both seizures and altered neurological status. The mean total physical dose of radiation was 41.63 Gy (± 4.33), range 24-45 Gy. In all but one cat (95.5%), neurological signs improved after radiation therapy. The median progression-free survival was 510 days (95% confidence interval [CI]: 51-969). The proportion free of progression at 1 year was 55.7% (95% CI: 33-78). Fourteen cats died (only in five cases was death related to the intracranial tumour) and eight cats were still alive or lost to follow-up. The median overall survival time was 515 days (95% CI: 66-964). None of the tested variables influenced outcome. CONCLUSIONS AND RELEVANCE Radiation therapy seems to represent a viable treatment option in cats with intracranial tumours, relieving neurological signs and improving local tumour control. Radiation therapy may be considered for cats with tumours in complicated/inoperable localisations or for cases with a high peri- and postoperative risk.
Collapse
Affiliation(s)
- Maximilian Körner
- 1 Divison of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Malgorzata Roos
- 2 Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Valeria S Meier
- 1 Divison of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Alena Soukup
- 1 Divison of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Simona Cancedda
- 3 Centro Oncologico Veterinario, Sasso Marconi, Bologna, Italy
| | - Magdalena M Parys
- 4 Royal (Dick) School of Veterinary Studies, Hospital for Small Animals, University of Edinburgh, Roslin, UK
| | - Michelle Turek
- 5 Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, USA
| | - Carla Rohrer Bley
- 1 Divison of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| |
Collapse
|
11
|
Rossi F, Körner M, Suárez J, Carozzi G, Meier VS, Roos M, Rohrer Bley C. Computed tomographic-lymphography as a complementary technique for lymph node staging in dogs with malignant tumors of various sites. Vet Radiol Ultrasound 2017; 59:155-162. [DOI: 10.1111/vru.12569] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 07/13/2017] [Accepted: 08/02/2017] [Indexed: 12/26/2022] Open
Affiliation(s)
- Federica Rossi
- Centro Oncologico Veterinario and Clinica Veterinaria dell'Orologio; Sasso Marconi (BO) I-40037 Italy
| | - Maximilian Körner
- Division of Radiation Oncology; University of Zurich; Zurich CH-8057 Switzerland
| | - José Suárez
- Clinic of Diagnostic Imaging; University of Zurich; Zurich CH-8057 Switzerland
| | - Gregorio Carozzi
- Centro Oncologico Veterinario and Clinica Veterinaria dell'Orologio; Sasso Marconi (BO) I-40037 Italy
| | - Valeria S. Meier
- Division of Radiation Oncology; University of Zurich; Zurich CH-8057 Switzerland
| | - Malgorzata Roos
- Department of Biostatistics; University of Zurich; Zurich CH-8001 Switzerland
| | - Carla Rohrer Bley
- Division of Radiation Oncology; University of Zurich; Zurich CH-8057 Switzerland
| |
Collapse
|
12
|
Meier VS, Rufle A, Gudat F. Simultaneous evaluation of T- and B-cell clonality, t(11;14) and t(14;18), in a single reaction by a four-color multiplex polymerase chain reaction assay and automated high-resolution fragment analysis: a method for the rapid molecular diagnosis of lymphoproliferative disorders applicable to fresh frozen and formalin-fixed, paraffin-embedded tissues, blood, and bone marrow aspirates. Am J Pathol 2001; 159:2031-43. [PMID: 11733354 PMCID: PMC1850583 DOI: 10.1016/s0002-9440(10)63055-6] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Current polymerase chain reaction (PCR) methods for the molecular diagnosis of B- and T-cell lymphomas by determination of clonality of immunoglobulin heavy chain (IgH) and T-cell receptor-gamma rearrangements and by detection of the chromosomal translocations t(14;18) and t(11;14), require several laborious and costly PCR assays for each of these diagnostic tests. We have developed a multiplex PCR assay for the simultaneous determination of B- and T-cell clonality and the detection of the chromosomal translocations t(14;18) and t(11;14) in a single reaction, using four-color fluorescence and automated high-resolution fragment analysis. The 26 primers combined in the multiplex PCR correspond to the sequences of >90% of the 69 variables and 6 join IgH genes and 100% of the T-cell receptor-gamma variables and join genes that could participate in the respective rearrangements. In addition, they detect the major and the minor breakpoint regions of the t(14;18) and the major breakpoint region of the t(11;14), and amplify the beta-globin gene as an internal control. The specificity of the multiplex PCR was confirmed by analysis of 39 T-cell lymphomas and 58 B-cell lymphomas, including 11 mantle cell lymphomas bearing the t(11;14) and 25 follicular lymphomas bearing the t(14;18), with known rearrangements and/or translocations. Fifteen samples of reactive lymphadenitis remained negative.
Collapse
MESH Headings
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Base Sequence
- Biopsy, Needle
- Bone Marrow/pathology
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/genetics
- Clone Cells
- DNA/chemistry
- DNA/genetics
- Fixatives
- Formaldehyde
- Frozen Sections
- Gene Rearrangement
- Genes, T-Cell Receptor gamma/genetics
- Humans
- Immunoglobulin Heavy Chains/genetics
- Jurkat Cells
- Lymphoma, T-Cell/genetics
- Lymphoma, T-Cell/pathology
- Lymphoproliferative Disorders/blood
- Lymphoproliferative Disorders/diagnosis
- Lymphoproliferative Disorders/genetics
- Molecular Sequence Data
- Paraffin Embedding
- Polymerase Chain Reaction/methods
- Sequence Analysis, DNA
- Sequence Homology, Nucleic Acid
- T-Lymphocytes/metabolism
- T-Lymphocytes/pathology
- Tissue Fixation
- Translocation, Genetic
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- V S Meier
- Institute for Pathology, University of Basel, Basel, Switzerland.
| | | | | |
Collapse
|
13
|
Meier VS, Kühne T, Jundt G, Gudat F. Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 1998; 7:29-35. [PMID: 9646032 DOI: 10.1097/00019606-199802000-00006] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Most Ewing tumors (ET), including Ewing sarcomas, peripheral primitive neuroectodermal tumors (PNET), and Askin's tumors, can be defined according to the specific chromosomal translocations t(11;22)(q24;q12) (EWS-FLI-1) or t(21;22)(q21;q12) (EWS-ERG). Detection of the chimeric RNA transcripts by reverse transcriptase-polymerase chain reaction (RT-PCR) has greatly facilitated the diagnosis of ET. Because of variable chromosomal breakpoint locations, however, the EWS gene fusions with FLI-1 and ERG genes are highly heterogenous, resulting in different sizes of the amplification products. To improve the diagnostic usefulness of the RT-PCR assay, we have developed an assay to detect chimeric mRNA transcripts by nested RT-PCR, followed by digestion of the PCR fragments with three different restriction endonucleases. This allows confirmation of the specificity of the PCR product and provides a rapid method to determine the combination of exons present in a transcript. In the 12 Ewing tumors tested, five different exon combinations were detected. In nine repeat biopsies of four patients, the case-specific translocation remained unchanged. One additional central PNET had no ET-specific translocation. In conclusion, the suggested combination of RT-PCR and restriction analysis of the PCR products allows a rapid and specific determination of ET-specific translocations.
Collapse
MESH Headings
- Adolescent
- Adult
- Child
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 21
- Chromosomes, Human, Pair 22
- DNA-Binding Proteins
- Exons/genetics
- Female
- Humans
- Male
- Oncogene Proteins/genetics
- Oncogene Proteins, Fusion/genetics
- Polymerase Chain Reaction
- Proto-Oncogene Protein c-fli-1
- RNA-Binding Protein EWS
- RNA-Directed DNA Polymerase
- Sarcoma, Ewing/diagnosis
- Sarcoma, Ewing/genetics
- Trans-Activators
- Transcription Factors/genetics
- Transcription, Genetic
- Transcriptional Regulator ERG
- Translocation, Genetic
Collapse
Affiliation(s)
- V S Meier
- Institute for Pathology, University of Basel, Switzerland
| | | | | | | |
Collapse
|
14
|
Standke GJ, Meier VS, Groner B. Mammary gland factor activated by prolactin on mammary epithelial cells and acute-phase response factor activated by interleukin-6 in liver cells share DNA binding and transactivation potential. Mol Endocrinol 1994; 8:469-77. [PMID: 7519723 DOI: 10.1210/mend.8.4.7519723] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
We have studied transcription factors that are coupled to the activation of cytokine receptors in liver and in mammary epithelial cells. Interleukin-6 (IL-6) causes the rapid activation of the acute-phase response factor (APRF) in the liver of animals during acute inflammation and in cultured human hepatoma cells (HepG2) and induces the transcription of the acute-phase protein genes, e.g. alpha 2-macroglobulin (alpha 2-M). In the mammary gland and in cultured HC11 mammary epithelial cells, milk protein genes, e.g. beta-casein, are induced by the lactogenic hormones, insulin, glucocorticoids, and PRL. The induction of the beta-casein gene promoter is preceded by the activation of the mammary gland factor (MGF). We have compared the DNA binding sequences of APRF and MGF, 5'-CTTCTT/GGGAATT-3', and have found that they coincide in 11 of 12 positions. Bandshift experiments and oligonucleotide competition experiments showed that both factors, MGF and APRF, are able to bind to the IL-6 response element of the alpha 2-M gene promoter and to the lactogenic hormone response element of the beta-casein gene promoter with very similar specificities. Partial proteolytic digestion of APRF and MGF DNA complexes yielded similar clipping patterns. The UV cross-linked DNA complexes of both transcription factors were of the same apparent molecular mass. IL-6 activation of APRF in HepG2 cells can be observed within minutes. MGF induction by PRL in HC11 cells occurs with similar kinetics. The synergistic action of glucocorticoids and PRL is necessary for the induction of the beta-casein gene, but PRL is sufficient for MGF activation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- G J Standke
- Friedrich Miescher-Institute, Basel, Switzerland
| | | | | |
Collapse
|
15
|
Meier VS, Groner B. The nuclear factor YY1 participates in repression of the beta-casein gene promoter in mammary epithelial cells and is counteracted by mammary gland factor during lactogenic hormone induction. Mol Cell Biol 1994; 14:128-37. [PMID: 8264581 PMCID: PMC358363 DOI: 10.1128/mcb.14.1.128-137.1994] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Expression of the beta-casein milk protein gene in the mammary epithelial cell line HC11 is primarily regulated at the transcriptional level. A 338-bp segment of promoter sequence 5' of the transcription start site is sufficient to confer inducibility by the lactogenic hormones insulin, glucocorticoid hormone, and prolactin. Positively and negatively acting promoter elements and specific DNA binding proteins have been identified. The binding of the mammary gland factor MGF to a site between -80 and -100 is indispensable for hormonal induction of transcription. Binding of MGF activity to DNA is greatly enhanced by the action of the lactogenic hormones. Repression of transcription in the uninduced state is mediated by a promoter element located adjacent to the MGF binding site at positions -110 to -150. This repressor element consists of two interacting protein binding sites. A nuclear factor that binds specifically to the proximal site between positions -110 and -120 has been characterized and found to be identical with the nuclear factor YY1 (delta, NF-E1). YY1 does not bind to the distal site. The simultaneous mutation in the proximal and the distal sites results in high, hormone-independent transcription. This finding suggests that YY1 plays a functional role in the repression and acts in conjunction with a second DNA binding protein. Comparison of YY1 DNA binding activity in uninduced and hormone-induced cells showed that relief of repression is not mediated by changes in the concentration or binding affinity of YY1. Infection of HC11 cells with a YY1-expressing recombinant retrovirus resulted in overexpression of YY1 but did not suppress hormonal induction. The addition of purified MGF decreased YY1 binding to its DNA recognition site in vitro. This finding indicates that MGF regulates the DNA binding activity of YY1 and thereby may cause the relief of transcriptional repression.
Collapse
Affiliation(s)
- V S Meier
- Friedrich Miescher Institute, Basel, Switzerland
| | | |
Collapse
|
16
|
Affiliation(s)
- V S Meier
- Institut für Molekularbiologie II, Universität Zürich, Switzerland
| | | | | |
Collapse
|